Biotechnology developer CNS Pharmaceuticals is working to advance the clinical trials of a novel brain cancer-fighting drug candidate with the aim of developing a new, effective therapy for treating an otherwise incurable disease The company plans a complex, multi-armed Phase 2 trial of its candidate Berubicin in hopes that the drug candidate may ultimately gain … Continue reading “CNS Pharmaceuticals (NASDAQ: CNSP) Outlines Plans for Advancing Drug It Hopes Will Beat Deadly Brain Cancer”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, will be joint sponsoring the 2020 Society of NeuroOncology (“SNO”) Virtual Meeting. CNS will be sharing sponsorship with WPD Pharmaceuticals. The virtual event is slated for Nov. 19–21, 2020. … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Joint Sponsor 2020 SNO Virtual Meeting”
CNS Pharmaceuticals (NASDAQ: CNSP) management will be participating in A.G.P.’s upcoming Virtual Healthcare Symposium. The symposium is scheduled for Nov. 19, 2020. Leaders of CNSP, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, will be part of the event, which includes one-on-one virtual … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in A.G.P. Healthcare Symposium”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for Berubicin in the treatment of Glioblastoma Multiforme (“GBM”). … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Files IND Application for Berubicin in Treatment of GBM”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has scheduled a webcast today during which it will be discussing its plan to submit a phase 2 clinical trial design for FDA review. The call, which will be moderated by … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosting Webcast for Discussion of Phase 2 Clinical Trial Design”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its plans to issue a video update at 4:30 p.m. ET on Nov. 12, 2020, to discuss the clinical trial design for its upcoming Phase 2 U.S. … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Unveil Adaptive Design for Berubicin Phase 2 Clinical Trial in Nov. 12 Webinar”
Houston-based CNS Pharmaceuticals is preparing to launch Phase 2 clinical testing of a novel brain cancer-fighting drug candidate called Berubicin early next year The biopharmaceutical company recently announced that a U.S.-based company contracted to make Berubicin has completed its production process and an Italian company working on a dual track in Europe is expected to … Continue reading “CNS Pharmaceuticals (NASDAQ: CNSP) Announces Completion of Drug Manufacturing for Brain Cancer Trial”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has through its European manufacturer, BSP Pharmaceuticals S.p.A. (“BSP”), finished manufacturing its lead drug candidate for upcoming Phase 2 clinical trials. Berubicin is CNSP’s lead drug candidate for the treatment of … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Drug for Clinical Trials”
Berubicin Expected to Commence Trials for the Treatment of Glioblastoma, An Aggressive Form of Brain Cancer Currently Considered Incurable Production of Berubicin Begins in the U.S. and Europe Dual Manufacturing Facilities Engaged to Reduce Supply Chain Interruptions IND for Berubicin Could Be Filed by Year End CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) expects to have an … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moves Closer to IND Filing as Manufacturing of Lead Drug Candidate Commences”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has completed the manufacturing process for Berubicin Drug Product. CNSP’s U.S. manufacturer, Pharmaceutics International Inc. (“Pii”), has finished manufacturing the drug, which is the company’s lead drug candidate for the treatment … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Manufacturing of Lead Drug Candidate”
